Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2022-10-28
2022-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary purpose of the study is to examine the importance of altered erythropoiesis for surface and intracellular erythrocyte proteins, the number of immature reticulocytes, and for the haematological characteristics of the erythrocyte, such as volume, haemoglobin concentration and concentration of glycosylated haemoglobin, to assess whether these can be used to identify changed erythropoiesis. Furthermore, the aim is to examine whether these parameters are affected by freezer storage of erythrocytes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
NCT03548766
Iron Metabolism in Dragon Boat Athletes
NCT01431118
Effects of Red Bull® on the Effects of Training and Haemodynamic Parameters
NCT04963556
Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury
NCT01000766
Methemoglobin Concentration in High Dose Inhaled Nitric Oxide
NCT05612074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Recombinant human erythropoietin treatment three times per week for three weeks
Recombinant human erythropoietin
Recombinant human erythropoietin treatment three times per week for three weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant human erythropoietin
Recombinant human erythropoietin treatment three times per week for three weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-40 years
* physical fitness rating more than 50ml/kg/min
* non-smokers
* blood pressure \<130/90 mmHg
* hemoglobin concentration 7-10.5 mM.
Exclusion Criteria
* Participation in other concurrent clinical trials
* To participate in competitive sport during or three months after the study.
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacob Bejder, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nutrition, Exercise and Sports
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-20064997
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.